POLICY PRIORITIES - APPLICATION 1
Delphi Results
Synthetic Biomaterials
Development, production and sale of synthetic biomaterials for clinical applications in human health
Plausibly available in the immediate future
(up to 5 years from now)
BENEFITS AND COSTS
What benefits are most relevant?
1. Strengthen basic biological research that is more relevant to human subjects than to animal models (μ=7,36; SD=1,37)
2. Biological solutions to the problem of shortage of human organs and tissues” (μ=7,04; SD=1,14)
Which stakeholders will mostly benefit?
1. Private biotechnology firms (μ=7,93; SD=1,15)
2. Patient’s organizations (μ=6,89; SD=1,31)
What costs are most relevant?
1. Difficulty to predict the long-term biological behaviour of synthetic biomaterials implanted in the human body (μ=6,89; SD=1,31)
2. Rise of new ethical issues concerning the production of artificial cells, tissues and organs (μ=6,64; SD=1,59)
Which stakeholders will have to bear the highest costs ?
1. National public health agencies (μ=6,32; SD=1,72)
2. Private biotechnology firms” (μ=6,04; SD=1,82)
Which stakeholders can have a relevant role in the allocation of costs and benefits ?
1. Policy Makers
2. Research Fundings
Which procedure should be used to asses the costs and benefits of the application?
1. Risk Assessment Procedures
GOVERNANCE AND REGULATORY TOOLS
Which governance framework should be used to regulate R&D activities ?
1. International guidelines” (μ=7,54; SD=1,10)
Which procedures should be used to foster compliance with regulatory measures ?
1. Legally binding procedures
2. Regularly monitored and evaluated through audit procedures
Which approaches are most useful in encouraging companies and research organization to comply with regulatory and governance?
1. Reputational Incentives (ethical labels, brands, and rankings) (μ=7,00; SD=1,41)
2. Requirement to integrate the adherence to the regulatory measures into research funding through evaluation criteria (μ=6,61; SD=1,34)